;PMID: 9001550
;source_file_772.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..29] = [t:0..29]
;1)sentence:[e:34..120] = [t:34..120]
;2)section:[e:124..246] = [t:124..246]
;3)section:[e:250..323] = [t:250..323]
;4)sentence:[e:327..338] = [t:327..338]
;5)sentence:[e:339..484] = [t:339..484]
;6)sentence:[e:485..623] = [t:485..623]
;7)sentence:[e:625..806] = [t:625..806]
;8)sentence:[e:807..815] = [t:807..815]
;9)sentence:[e:816..967] = [t:816..967]
;10)sentence:[e:968..1090] = [t:968..1090]
;11)sentence:[e:1091..1163] = [t:1091..1163]
;12)sentence:[e:1164..1277] = [t:1164..1277]
;13)sentence:[e:1278..1439] = [t:1278..1439]
;14)sentence:[e:1440..1448] = [t:1440..1448]
;15)sentence:[e:1449..1584] = [t:1449..1584]
;16)sentence:[e:1585..1652] = [t:1585..1652]
;17)sentence:[e:1654..1666] = [t:1654..1666]
;18)sentence:[e:1667..1893] = [t:1667..1893]
;19)section:[e:1897..1941] = [t:1897..1941]

;section 0 Span:0..29
;Surgery  1997 Jan;121(1):42-9
(SEC
  (FRAG (IN:[0..7] Surgery) (CD:[9..13] 1997) (CC:[14..22] Jan;121-LRB-)
        (CD:[22..23] 1) (-RRB-:[23..24] -RRB-) (CD:[24..27] :42) (::[27..28] -)
        (CD:[28..29] 9)))

;sentence 1 Span:34..120
;Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal 
;hyperplasia.
;[46..51]:gene-rna:"K-ras"
;[74..119]:malignancy:"chronic pancreatitis with ductal  hyperplasia"
(SENT
  (NP-HLN
    (NP (NN:[34..42] Analysis))
    (PP (IN:[43..45] of)
      (NP
        (NP (NN:[46..51] K-ras) (NN:[52..60] oncogene) (NNS:[61..70] mutations))
        (PP (IN:[71..73] in)
          (NP (JJ:[74..81] chronic) (NN:[82..94] pancreatitis)))
        (PP (IN:[95..99] with)
          (NP (JJ:[100..106] ductal) (NN:[108..119] hyperplasia)))))
    (.:[119..120] .)))

;section 2 Span:124..246
;Rivera JA, Rall CJ, Graeme-Cook F, Fernandez-del Castillo C, Shu P, Lakey N, 
;Tepper R, Rattner DW, Warshaw AL, Rustgi AK.
(SEC
  (FRAG (NNP:[124..130] Rivera) (NNP:[131..133] JA) (,:[133..134] ,)
        (NNP:[135..139] Rall) (NNP:[140..142] CJ) (,:[142..143] ,)
        (NNP:[144..150] Graeme) (::[150..151] -) (NNP:[151..155] Cook)
        (NNP:[156..157] F) (NNP:[157..158] ,) (NNP:[159..168] Fernandez)
        (::[168..169] -) (DT:[169..172] del) (NNP:[173..181] Castillo)
        (NNP:[182..183] C) (,:[183..184] ,) (NNP:[185..188] Shu)
        (NNP:[189..190] P) (,:[190..191] ,) (NNP:[192..197] Lakey)
        (NNP:[198..199] N) (,:[199..200] ,) (NNP:[202..208] Tepper)
        (NNP:[209..211] R,) (NNP:[212..219] Rattner) (NNP:[220..222] DW)
        (,:[222..223] ,) (NNP:[224..231] Warshaw) (NNP:[232..234] AL)
        (,:[234..235] ,) (NNP:[236..242] Rustgi) (NNP:[243..246] AK.)))

;section 3 Span:250..323
;Department of Surgery, Massachusetts General Hospital, Boston 02114, USA.
(SEC
  (FRAG (NNP:[250..260] Department) (IN:[261..263] of) (NNP:[264..271] Surgery)
        (,:[271..272] ,) (NNP:[273..286] Massachusetts) (NNP:[287..294] General)
        (NNP:[295..303] Hospital) (,:[303..304] ,) (NNP:[305..311] Boston)
        (VBD:[312..317] 02114) (NNP:[317..318] ,) (NNP:[319..322] USA)
        (.:[322..323] .)))

;sentence 4 Span:327..338
;BACKGROUND:
(SENT
  (NP (NN:[327..337] BACKGROUND) (::[337..338] :)))

;sentence 5 Span:339..484
;K-ras oncogene mutations have been identified in up to 95% of  pancreatic
;cancers, implying their critical role in their molecular  pathogenesis.
;[339..344]:gene-rna:"K-ras"
;[402..420]:malignancy:"pancreatic cancers"
(SENT
  (S
    (NP-SBJ-1 (NN:[339..344] K-ras) (NN:[345..353] oncogene)
              (NNS:[354..363] mutations))
    (VP (VBP:[364..368] have)
      (VP (VBN:[369..373] been)
        (VP (VBN:[374..384] identified)
          (NP-1 (-NONE-:[384..384] *))
          (PP (IN:[385..387] in)
            (NP
              (NP
                (QP (RB:[388..390] up) (TO:[391..393] to) (CD:[394..396] 95))
                (NN:[396..397] %))
              (PP (IN:[398..400] of)
                (NP (JJ:[402..412] pancreatic) (NNS:[413..420] cancers)))))
          (,:[420..421] ,)
          (S-ADV
            (NP-SBJ (-NONE-:[421..421] *))
            (VP (VBG:[422..430] implying)
              (NP
                (NP (PRP$:[431..436] their) (JJ:[437..445] critical)
                    (NN:[446..450] role))
                (PP (IN:[451..453] in)
                  (NP (PRP$:[454..459] their) (JJ:[460..469] molecular)
                      (NN:[471..483] pathogenesis)))))))))
    (.:[483..484] .)))

;sentence 6 Span:485..623
;However, the earliest stage in which K-ras mutations can be  detected in
;potential precursor lesions of pancreatic cancer remains unclear.
;[522..527]:gene-rna:"K-ras"
;[568..606]:malignancy:"precursor lesions of pancreatic cancer"
(SENT
  (S
    (ADVP (RB:[485..492] However))
    (,:[492..493] ,)
    (NP-SBJ
      (NP (DT:[494..497] the) (JJS:[498..506] earliest) (NN:[507..512] stage))
      (SBAR
        (WHPP-2 (IN:[513..515] in)
          (WHNP (WDT:[516..521] which)))
        (S
          (NP-SBJ-1 (NN:[522..527] K-ras) (NNS:[528..537] mutations))
          (VP (MD:[538..541] can)
            (VP (VB:[542..544] be)
              (VP (VBN:[546..554] detected)
                (NP-1 (-NONE-:[554..554] *))
                (PP-LOC (IN:[555..557] in)
                  (NP
                    (NP (JJ:[558..567] potential) (NN:[568..577] precursor)
                        (NNS:[578..585] lesions))
                    (PP (IN:[586..588] of)
                      (NP (JJ:[589..599] pancreatic) (NN:[600..606] cancer)))))
                (PP-2 (-NONE-:[606..606] *T*))))))))
    (VP (VBZ:[607..614] remains)
      (ADJP-PRD (JJ:[615..622] unclear)))
    (.:[622..623] .)))

;sentence 7 Span:625..806
;This study evaluates pancreatic ductal hyperplasia in the setting of chronic 
;pancreatitis, which predisposes to pancreatic cancer development, for K-ras 
;codon 12 and 13 mutations.
;[646..715]:malignancy:"pancreatic ductal hyperplasia in the setting of
;chronic  pancreatitis"
;[738..755]:malignancy:"pancreatic cancer"
;[773..778]:gene-rna:"K-ras"
;[780..788]:variation-location:"codon 12"
;[780..785]...[793..795]:variation-location:"codon"..."13"
;[796..805]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ (DT:[625..629] This) (NN:[630..635] study))
    (VP (VBZ:[636..645] evaluates)
      (NP (JJ:[646..656] pancreatic) (JJ:[657..663] ductal)
          (NN:[664..675] hyperplasia))
      (PP (IN:[676..678] in)
        (NP
          (NP (DT:[679..682] the) (NN:[683..690] setting))
          (PP (IN:[691..693] of)
            (NP
              (NP (JJ:[694..701] chronic) (NN:[703..715] pancreatitis))
              (,:[715..716] ,)
              (SBAR
                (WHNP-1 (WDT:[717..722] which))
                (S
                  (NP-SBJ-1 (-NONE-:[722..722] *T*))
                  (VP (VBZ:[723..734] predisposes)
                    (PP (TO:[735..737] to)
                      (NP
                         (JJ:[738..748] pancreatic) (NN:[749..755] cancer)
                        (NN:[756..767] development))))))))))
      (,:[767..768] ,)
      (PP-PRP (IN:[769..772] for)
        (NP
          (NP
            (NML-3 (NN:[773..778] K-ras))
            (NML
              (NML-2 (NN:[780..785] codon))
              (CD:[786..788] 12))
            (NML-4 (-NONE-:[788..788] *P*)))
          (CC:[789..792] and)
          (NP
            (NML-3 (-NONE-:[792..792] *P*))
            (NML
              (NML-2 (-NONE-:[792..792] *P*))
              (CD:[793..795] 13))
            (NML-4 (NNS:[796..805] mutations))))))
    (.:[805..806] .)))

;sentence 8 Span:807..815
;METHODS:
(SENT
  (NP (NNS:[807..814] METHODS) (::[814..815] :)))

;sentence 9 Span:816..967
;Paraffin-embedded surgical specimens from 42  patients with chronic
;pancreatitis were examined microscopically for the  presence of ductal
;hyperplasia.
;[876..896]:malignancy:"chronic pancreatitis"
;[948..966]:malignancy:"ductal hyperplasia"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (ADJP (NN:[816..824] Paraffin) (HYPH:[824..825] -)
              (VBN:[825..833] embedded))
        (JJ:[834..842] surgical) (NNS:[843..852] specimens))
      (PP (IN:[853..857] from)
        (NP
          (NP (CD:[858..860] 42) (NNS:[862..870] patients))
          (PP (IN:[871..875] with)
            (NP (JJ:[876..883] chronic) (NN:[884..896] pancreatitis))))))
    (VP (VBD:[897..901] were)
      (VP (VBN:[902..910] examined)
        (NP-1 (-NONE-:[910..910] *))
        (ADVP (RB:[911..926] microscopically))
        (PP-PRP (IN:[927..930] for)
          (NP
            (NP (DT:[931..934] the) (NN:[936..944] presence))
            (PP (IN:[945..947] of)
              (NP (JJ:[948..954] ductal) (NN:[955..966] hyperplasia)))))))
    (.:[966..967] .)))

;sentence 10 Span:968..1090
;Both hyperplastic and nonhyperplastic ducts were  microdissected from the
;specimens that contained hyperplasia (11 of 42).
;[973..985]:malignancy:"hyperplastic"
;[1067..1078]:malignancy:"hyperplasia"
(SENT
  (S
    (NP-SBJ-3 (CC:[968..972] Both)
      (NP (JJ:[973..985] hyperplastic)
        (NML-1 (-NONE-:[985..985] *P*)))
      (CC:[986..989] and)
      (NP (JJ:[990..1005] nonhyperplastic)
        (NML-1 (NNS:[1006..1011] ducts))))
    (VP (VBD:[1012..1016] were)
      (VP (VBN:[1018..1032] microdissected)
        (NP-3 (-NONE-:[1032..1032] *))
        (PP (IN:[1033..1037] from)
          (NP
            (NP (DT:[1038..1041] the) (NNS:[1042..1051] specimens))
            (SBAR
              (WHNP-2 (WDT:[1052..1056] that))
              (S
                (NP-SBJ-2 (-NONE-:[1056..1056] *T*))
                (VP (VBD:[1057..1066] contained)
                  (NP (NN:[1067..1078] hyperplasia)))))
            (PRN (-LRB-:[1079..1080] -LRB-)
              (NP
                (NP (CD:[1080..1082] 11))
                (PP (TO:[1083..1085] of)
                  (NP (CD:[1086..1088] 42))))
              (-RRB-:[1088..1089] -RRB-))))))
    (.:[1089..1090] .)))

;sentence 11 Span:1091..1163
;Four of  the remaining specimens without hyperplasia served as controls.
;[1132..1143]:malignancy:"hyperplasia"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1091..1095] Four))
      (PP (IN:[1096..1098] of)
        (NP (DT:[1100..1103] the) (VBG:[1104..1113] remaining)
            (NNS:[1114..1123] specimens)))
      (PP (IN:[1124..1131] without)
        (NP (NN:[1132..1143] hyperplasia))))
    (VP (VBD:[1144..1150] served)
      (PP-CLR (IN:[1151..1153] as)
        (NP (NNS:[1154..1162] controls))))
    (.:[1162..1163] .)))

;sentence 12 Span:1164..1277
;Genomic DNA was  extracted, and polymerase chain reaction and amplification
;of the K-ras oncogene  was performed.
;[1196..1206]:gene-protein:"polymerase"
;[1247..1252]:gene-rna:"K-ras"
(SENT
  (S
    (S
      (NP-SBJ-1 (JJ:[1164..1171] Genomic) (NN:[1172..1175] DNA))
      (VP (VBD:[1176..1179] was)
        (VP (VBN:[1181..1190] extracted)
          (NP-1 (-NONE-:[1190..1190] *)))))
    (,:[1190..1191] ,) (CC:[1192..1195] and)
    (S
      (NP-SBJ-2
        (NP (NN:[1196..1206] polymerase) (NN:[1207..1212] chain)
            (NN:[1213..1221] reaction))
        (CC:[1222..1225] and)
        (NP
          (NP (NN:[1226..1239] amplification))
          (PP (IN:[1240..1242] of)
            (NP (DT:[1243..1246] the) (NN:[1247..1252] K-ras)
                (NN:[1253..1261] oncogene)))))
      (VP (VBD:[1263..1266] was)
        (VP (VBN:[1267..1276] performed)
          (NP-2 (-NONE-:[1276..1276] *)))))
    (.:[1276..1277] .)))

;sentence 13 Span:1278..1439
;Polymerase chain reaction products were evaluated by means of  hybridization
;to mutant specific oligonucleotide probes and by means of  automated DNA
;sequencing.
;[1278..1288]:gene-protein:"Polymerase"
(SENT
  (S
    (NP-1
      (NML (NN:[1278..1288] Polymerase) (NN:[1289..1294] chain)
           (NN:[1295..1303] reaction))
      (NNS:[1304..1312] products))
    (VP (VBD:[1313..1317] were)
      (VP (VBN:[1318..1327] evaluated)
        (NP-1 (-NONE-:[1327..1327] *T*))
        (PP-MNR
          (PP (IN:[1328..1330] by)
            (NP
              (NP (NNS:[1331..1336] means))
              (PP (IN:[1337..1339] of)
                (NP
                  (NP (NN:[1341..1354] hybridization))
                  (PP (TO:[1355..1357] to)
                    (NP
                      (ADJP (JJ:[1358..1364] mutant) (JJ:[1365..1373] specific))
                      (NN:[1374..1389] oligonucleotide)
                       (NNS:[1390..1396] probes)))))))
          (CC:[1397..1400] and)
          (PP (IN:[1401..1403] by)
            (NP
              (NP (NNS:[1404..1409] means))
              (PP (IN:[1410..1412] of)
                (NP (JJ:[1414..1423] automated) (NN:[1424..1427] DNA)
                    (NN:[1428..1438] sequencing))))))))
    (.:[1438..1439] .)))

;sentence 14 Span:1440..1448
;RESULTS:
(SENT
  (NP (NNS:[1440..1447] RESULTS) (::[1447..1448] :)))

;sentence 15 Span:1449..1584
;K-ras codon 12 mutations representing glycine  to valine substitutions were
;present in 2 of (18%) 11 patients with ductal  hyperplasia.
;[1449..1454]:gene-rna:"K-ras"
;[1455..1463]:variation-location:"codon 12"
;[1464..1473]:variation-event:"mutations"
;[1487..1494]:variation-state-original:"glycine"
;[1499..1505]:variation-state-altered:"valine"
;[1506..1519]:variation-type:"substitutions"
;[1564..1583]:malignancy:"ductal  hyperplasia"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1449..1454] K-ras)
        (NML (NN:[1455..1460] codon) (CD:[1461..1463] 12))
        (NNS:[1464..1473] mutations))
      (VP (VBG:[1474..1486] representing)
        (NP
          (NML
            (NML (NN:[1487..1494] glycine))
            (PP (TO:[1496..1498] to)
              (NML (NN:[1499..1505] valine))))
          (NNS:[1506..1519] substitutions))))
    (VP (VBD:[1520..1524] were)
      (ADJP-PRD (JJ:[1525..1532] present))
      (PP (IN:[1533..1535] in)
        (NP
          (NP (CD:[1536..1537] 2))
          (PP (IN:[1538..1540] of)
            (NP
              (PRN (-LRB-:[1541..1542] -LRB-) (CD:[1542..1544] 18)
                   (NN:[1544..1545] %) (-RRB-:[1545..1546] -RRB-))
              (NP (CD:[1547..1549] 11) (NNS:[1550..1558] patients))
              (PP (IN:[1559..1563] with)
                (NP (JJ:[1564..1570] ductal) (NN:[1572..1583] hyperplasia))))))))
    (.:[1583..1584] .)))

;sentence 16 Span:1585..1652
;No mutations were found in the controls without ductal hyperplasia.
;[1588..1597]:variation-event:"mutations"
;[1633..1651]:malignancy:"ductal hyperplasia"
(SENT
  (S
    (NP-SBJ-1 (DT:[1585..1587] No) (NNS:[1588..1597] mutations))
    (VP (VBD:[1598..1602] were)
      (VP (VBN:[1603..1608] found)
        (NP-1 (-NONE-:[1608..1608] *))
        (PP (IN:[1609..1611] in)
          (NP
            (NP (DT:[1612..1615] the) (NNS:[1616..1624] controls))
            (PP (IN:[1625..1632] without)
              (NP (JJ:[1633..1639] ductal) (NN:[1640..1651] hyperplasia)))))))
    (.:[1651..1652] .)))

;sentence 17 Span:1654..1666
;CONCLUSIONS:
(SENT
  (NP (NNS:[1654..1665] CONCLUSIONS) (::[1665..1666] :)))

;sentence 18 Span:1667..1893
;Our study supports the premise that K-ras mutations develop in a  subset of
;chronic pancreatitis associated hyperplasia and provides a genetic  basis for
;the potential progression of chronic pancreatitis to pancreatic  cancer.
;[1703..1708]:gene-rna:"K-ras"
;[1743..1786]:malignancy:"chronic pancreatitis associated hyperplasia"
;[1850..1870]:malignancy:"chronic pancreatitis"
;[1874..1892]:malignancy:"pancreatic  cancer"
(SENT
  (S
    (NP-SBJ (PRP$:[1667..1670] Our) (NN:[1671..1676] study))
    (VP
      (VP (VBZ:[1677..1685] supports)
        (NP (DT:[1686..1689] the) (NN:[1690..1697] premise)
          (SBAR (IN:[1698..1702] that)
            (S
              (NP-SBJ (NN:[1703..1708] K-ras) (NNS:[1709..1718] mutations))
              (VP (VBP:[1719..1726] develop)
                (PP (IN:[1727..1729] in)
                  (NP
                    (NP (DT:[1730..1731] a) (NN:[1733..1739] subset))
                    (PP (IN:[1740..1742] of)
                      (NP
                        (ADJP
                          (NML (JJ:[1743..1750] chronic)
                               (NN:[1751..1763] pancreatitis))
                          (VBN:[1764..1774] associated))
                        (NN:[1775..1786] hyperplasia))))))))))
      (CC:[1787..1790] and)
      (VP (VBZ:[1791..1799] provides)
        (NP
          (NP (DT:[1800..1801] a) (JJ:[1802..1809] genetic)
              (NN:[1811..1816] basis))
          (PP (IN:[1817..1820] for)
            (NP
              (NP (DT:[1821..1824] the) (JJ:[1825..1834] potential)
                  (NN:[1835..1846] progression))
              (PP (IN:[1847..1849] of)
                (NP (JJ:[1850..1857] chronic) (NN:[1858..1870] pancreatitis)))
              (PP (TO:[1871..1873] to)
                (NP (JJ:[1874..1884] pancreatic) (NN:[1886..1892] cancer))))))))
    (.:[1892..1893] .)))

;section 19 Span:1897..1941
;PMID: 9001550 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1897..1901] PMID) (::[1901..1902] :) (CD:[1903..1910] 9001550)
        (NN:[1911..1912] -LSB-) (NNP:[1912..1918] PubMed) (::[1919..1920] -)
        (NN:[1921..1928] indexed) (IN:[1929..1932] for)
        (NNP:[1933..1941] MEDLINE-RSB-)))
